VBL Therapeutics

190 articles with VBL Therapeutics

• VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17

  5/10/2022

  VBL Therapeutics announced that it will release first quarter financial results for the period ended March 31, 2022 on Tuesday, May 17 before market open.

• VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May 2022

  5/3/2022

  VBL Therapeutics announced that the company will present new data on its novel Monocyte Targeting Technology and lead candidate VB-601 at IMMUNOLOGY2022TM being held in Portland, OR on May 6 – 10, 2022.

• VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Apr 28, 2022

  4/28/2022

  VBL Therapeutics announced that the Compensation Committee of VBL’s Board of Directors approved the grant effective April 24, 2022 of a non-qualified stock option to purchase an aggregate of 75,000 ordinary shares of VBL as an inducement material to the hiring of a new employee, in accordance with Nasdaq Listing Rule 5635.

• 

  Editas, VBL and Pharming Score Regulatory Wins On Development Journey

  4/26/2022

  Editas Medicine snagged Rare Pediatric Disease designation for its experimental beta thalassemia gene therapy, while VBL received Fast Track designation for an ofra-vec combination in ovarian cancer.

• VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer

  4/26/2022

  VBL Therapeutics (Nasdaq: VBLT), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ofra-vec (ofranergene obadenovec or VB-111) in combination with paclitaxel for the treatment of platinum-resistant ovarian cancer.

• VBL Therapeutics to Host In-Person Key Opinion Leader Seminar on Ovarian Cancer

  3/31/2022

  VBL Therapeutics today announced that it will host a key opinion leader (KOL) luncheon and seminar on ovarian cancer on Monday, April 11, 2022 at 12pm Eastern Time at the St. Regis Hotel in New York, NY.

• VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update

  3/23/2022

  VBL Therapeutics today announced financial results for the fiscal year ended December 31, 2021, and provided a corporate update.

• VLB Therapeutics to Report Year-End 2021 Financial Results on March 23

  3/14/2022

  VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it will release financial results for the year ended December 31, 2021 on Wednesday, March 23 before market open.

• UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23

  3/14/2022

  VBL Therapeutics today announced that it will release financial results for the year ended December 31, 2021 on Wednesday, March 23 before market open.

• VBL Therapeutics Announces Completion of Enrollment in OVAL Phase 3 Registration-Enabling Trial of Ofra-Vec in Ovarian Cancer and Unanimous Recommendation by Independent Data Safety Monitoring Committee to Continue Study as Planned

  3/8/2022

  VBL Therapeutics, a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, announced that enrollment in the Phase 3 OVAL trial in recurrent platinum-resistant ovarian cancer has been completed, with a total of 409 patients enrolled globally.

• VBL Therapeutics to Participate at March 2022 Investor Conferences

  3/3/2022

  VBL Therapeutics announced that management will participate in a fireside chat at the 34th Annual Roth Conference being held on March 13 - 15, 2022 as well as at the 32nd Annual Oppenheimer Healthcare Conference taking place on March 15 - 17, 2022.

• VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Feb 15, 2022

  2/15/2022

  VBL Therapeutics announced that the Compensation Committee of VBL’s Board of Directors approved the grant effective February 13, 2022 of a non-qualified stock option to purchase an aggregate of 300,000 ordinary shares of VBL as an inducement material to Matthew Trudeau entering into employment with VBL in accordance with Nasdaq Listing Rule 5635.

• VBL Therapeutics to Participate in the Guggenheim Oncology Conference and the 2022 BIO CEO & Investor Conference

  2/2/2022

  VBL Therapeutics announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will participate in a fireside chat at the Guggenheim Oncology Conference being held virtually on February 9 – 11, 2022.

• VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer

  1/18/2022

  VBL Therapeutics today announced the appointment of Matthew Trudeau to the newly created position of Chief Commercial Officer (CCO).

• VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

  1/6/2022

  VBL Therapeutics announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will present a corporate overview at the H.C. Wainwright BioConnect Virtual Conference being held on January 10 – 13, 2022.

• VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator Program

  12/20/2021

  VBL today announced that it has been selected for €17.5 million of blended funding by the European Innovation Council (EIC) Accelerator.

• VBL Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

  11/15/2021

  VBL Therapeutics, a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, announced financial results for the third quarter ended September 30, 2021, and provided a corporate update.

• VBL Therapeutics to Report Third Quarter Financial Results on November 15

  11/8/2021

  VBL Therapeutics (Nasdaq: VBLT), a clinical stage company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it will release third quarter financial results for the period ended September 30, 2021 on Monday, November 15 before market open.

• 

  BioSpace Movers & Shakers, Oct. 8

  10/8/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States

  10/5/2021

  VBL Therapeutics (Nasdaq: VBLT ) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective immediately.